An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis
Status:
Completed
Trial end date:
2019-02-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the superiority of CNTO 1959 (guselkumab) to
placebo in the treatment of participants with moderate to severe plaque-type psoriasis (A
common genetically determined, chronic, inflammatory skin disease characterized by rounded
erythematous, dry, scaling patches).